Susquehanna International Group
PTIXW

Susquehanna International Group’s Protagenic Therapeutics Warrant PTIXW Stock Holding History

Susquehanna International Group’s Portfolio PTIXW Stock Details PTIXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-87,596
Closed -$2.71K – 13915
2025
Q4 		$2.71K Hold
87,596
– – ﹤0.01% 12118
2025
Q3 		$2.24K Buy
87,596
+62,218
+245% +$2.98K ﹤0.01% 12165
2025
Q2 		$1.45K Sell
25,378
-24,806
-49% -$895 ﹤0.01% 12502
2025
Q1 		$376 Sell
50,184
-16,989
-25% -$87 ﹤0.01% 12347
2024
Q4 		$302 Buy
67,173
+20,558
+44% +$183 ﹤0.01% 12061
2024
Q3 		$420 Buy
46,615
+20,015
+75% +$228 ﹤0.01% 11829
2024
Q2 		$218 Buy
+26,600
New +$537 ﹤0.01% 11900
2023
Q3 		– Sell
-11,327
Closed -$379 – 12768
2023
Q2 		$379 Sell
11,327
-4,184
-27% -$131 ﹤0.01% 11925
2023
Q1 		$372 Sell
15,511
-8,453
-35% -$438 ﹤0.01% 12441
2022
Q4 		$527 Buy
23,964
+4,124
+21% +$151 ﹤0.01% 12210
2022
Q3 		$1K Sell
19,840
-6,879
-26% -$534 ﹤0.01% 12990
2022
Q2 		$4K Buy
+26,719
New +$3.46K ﹤0.01% 12626

Susquehanna International Group's PTIXW Position: Q1 2026 in Review

Susquehanna International Group sold out of Protagenic Therapeutics Warrant (PTIXW) in Q1 2026, closing a stake of 87,596 shares — an estimated $2.71K sold.

Susquehanna International Group first reported a position in PTIXW in Q2 2022 and held it in 12 quarters. The position peaked at $4K in Q2 2022. 0 funds tracked by Wall St. Rank hold PTIXW as of Q1 2026.

  • Susquehanna International Group reported no remaining Protagenic Therapeutics Warrant position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 87,596 Protagenic Therapeutics Warrant shares in Q1 2026, an estimated $2.71K.
  • Susquehanna International Group first reported a position in Protagenic Therapeutics Warrant in Q2 2022 and held it in 12 quarters.
  • Susquehanna International Group's Protagenic Therapeutics Warrant position peaked at $4K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Protagenic Therapeutics Warrant as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.